Ilumya
Ilumya ingredients
| Active ingredient | Strength |
|---|---|
| Tildrakizumab | 100 mg/mL |
What Ilumya is used for
The FDA lists the approved uses on the official label (below). In the EU, tildrakizumab is approved as Ilumetri for:
Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Ilumya
- Generic name
- Tildrakizumab-asmn
- Made by
- Sun Pharmaceutical Industries, Inc.
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- Interleukin-23 Antagonist
- FDA approval
- Biologic licence (BLA) BLA761067
- On the US market since
- 2018
Official information
- MedlinePlus drug information (search for Tildrakizumab-asmn)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ilumya?
Ilumya (Tildrakizumab-asmn) is a specialist medicine made by Sun Pharmaceutical Industries, Inc., approved by the US FDA.
What are the ingredients of Ilumya?
Ilumya contains Tildrakizumab (100 mg/mL).
Is Ilumya approved in Europe?
The same active substance is approved in the EU as Ilumetri.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA